ALMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the investor's beginner level, long-term strategy, and available capital, Alumis Inc (ALMS) is not a strong buy at the moment. Despite positive analyst sentiment and insider buying trends, the recent negative price momentum, lack of immediate trading signals, and weak financial performance suggest waiting for a better entry point.
The MACD is negative and expanding (-0.36), indicating bearish momentum. RSI is neutral at 40.864, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 27.043, with resistance at 29.786. The stock closed at $27.6, below the pivot of 28.415, suggesting weakness.
Strong analyst ratings with multiple Buy ratings and price targets ranging from $32 to $50, reflecting confidence in the company's lead asset, envudeucitinib.
Insider buying has surged by 586.17% in the last month, indicating confidence from company insiders.
Positive Phase 3 clinical trial results for envudeucitinib, which strengthens the investment narrative.
Recent price performance is negative, with a -4.26% drop in regular trading and -1.25% pre-market decline.
Financial performance is weak, with a net income loss of -$110.75M in Q3 2025 and a YoY EPS drop of -38.01%.
No significant hedge fund activity or recent congress trading data to support institutional confidence.
In Q3 2025, revenue remained flat YoY at $2.066M. Net income improved by 18.94% YoY but remains negative at -$110.75M. EPS dropped significantly by -38.01% YoY to -1.06. Gross margin is strong at 100%, but overall financials indicate a lack of profitability.
Analysts are highly optimistic, with multiple Buy ratings and price targets ranging from $32 to $50. Positive sentiment is driven by the strong Phase 3 trial results of envudeucitinib and its potential to dominate the TYK2 inhibitor market.
